
Mike Sharma, MD, MSc, discusses how asundexian’s approval revolutionizes secondary stroke prevention – and may provide a pathway to treat many more conditions.

Mike Sharma, MD, MSc, is the director of the stroke program at Hamilton Health Sciences and the Michael G. DeGroote Chair in Stroke Prevention at McMaster University.